REGENXBIO, Inc. Stockholders Should Contact Robbins LLP for Information About Leading the RGNX Class Action

Core Viewpoint - A class action lawsuit has been filed against REGENXBIO, Inc. for allegedly misleading investors about the viability of its drug candidate RGX-111, which is intended for the treatment of MPS I [2][3]. Group 1: Class Action Details - The class action is on behalf of all investors who purchased REGENXBIO securities between February 9, 2022, and January 27, 2026 [1]. - Allegations include that REGENXBIO misrepresented the safety and efficacy of RGX-111, despite knowing about serious safety issues, including the potential for CNS neoplasm [2][3]. - Following the announcement of a clinical hold by the FDA on RGX-111 due to a case of neoplasm, REGENXBIO's stock price dropped from $13.41 to $11.01, a decline of 17.8% in one day [3]. Group 2: Shareholder Actions - Shareholders interested in participating as lead plaintiffs must submit their papers by April 14, 2026 [4]. - Shareholders can choose to remain absent from the case while still being eligible for recovery [4]. Group 3: Company Background - REGENXBIO, Inc. is a clinical-stage biotechnology company focused on gene therapies that deliver functional genes to cells with genetic defects in the United States [1].